News
Sarepta Will Resume Gene Therapy Shipments
Digest more
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' gene therapy Elevidys for a type of rare ...
European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback